Mark Alles

Celgene raised Revlimid's price to meet aggressive sales targets

Celgene hiked prices on its cancer blockbuster Revlimid to hit aggressive sales targets or cover for expected shortfalls, a congressional report says.

Eric Sagonowsky Sep 30, 2020 9:30am

Taiho, Otsuka, Chugai, Biocon and Mark Alles—FiercePharmaAsia

Jan 10, 2020 10:59am

Bristol bumps Lynch, recruits Novartis vet for post-merger team

Jun 5, 2019 11:16am

BMS-Celgene integration questions? Execs aren't answering

Apr 26, 2019 11:45am

Investors aim to spotlight ties between pricing, exec pay

Apr 23, 2019 11:29am

Alexion chief nabs $16.5M in 2018

Mar 27, 2019 12:20pm